Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity

Blood

Volumn 114, Issue 17, 2009, Pages 3684-3692

  Stumpf, Anita N ^a   Van Der Meijden, Edith D ^a   Van Bergen, Cornelis A M ^a   Willemze, Roel ^a   Falkenburg, J H Frederik ^a   Griffioen, Marieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SKIN FIBROBLAST; TREATMENT OUTCOME;

EID: 70449494105     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2009-03-208017     Document Type: Article

References (52)

1. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330(2):100-106.
2. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041-2050.
3. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15(2):433-444. (Pubitemid 27074209)
4. Falkenburg JHF, van de Corput L, Marijt WAF, Willemze R. Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol. 2003;31(9):743-751. (Pubitemid 37075966)
5. den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 1995;268(5216):1476-1480.
6. den Haan JM, Meadows LM, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279(5353):1054-1057. (Pubitemid 28113311)
7. Dolstra H, Fredrix H, Maas F, et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med. 1999;189(2):301-308. (Pubitemid 29063251)
8. Brickner AG, Warren EH, Caldwell JA, et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med. 2001;193(2):195-206.
9. Akatsuka Y, Nishida T, Kondo E, et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med. 2003;197(11):1489-1500. (Pubitemid 36682546)
10. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med. 2003;197(10):1279-1289. (Pubitemid 36617774)
11. Spierings E, Brickner AG, Caldwell JA, et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood. 2003;102(2):621-629. (Pubitemid 36841984)
12. de Rijke B, van Horssen-Zoetbrood A, Beekman JM, et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest. 2005;115(12):3506-3516.
13. Brickner AG, Evans AM, Mito JK, et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood. 2006;107(9):3779-3786.
14. Slager EH, Honders MW, van der Meijden ED, et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood. 2006;107(12):4954-4960.
15. Warren EH, Vigneron NJ, Gavin MA, et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science. 2006;313(5792):1444- 1447.
16. van Bergen CAM, Kester MGD, Jedema I, et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood. 2007;109(9):4089-4096. (Pubitemid 46641765)
17. Kawase T, Akatsuka Y, Torikai H, et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood. 2007;110(3):1055-1063. (Pubitemid 47267448)
18. Marijt WAF, Heemskerk MHM, Kloosterboer FM, et al. Hematopoiesis- restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A. 2003;100(5):2742-2747.
19. Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003;17(4):187-194.
20. Toes REM, Schoenberger SP, van der Voort EI, Offringa R, Melief CJM. CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol. 1998;10(6):443-448. (Pubitemid 28564373)
21. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421(6925):852-856.
22. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003;300(5617):337-339. (Pubitemid 36433726)
23. Faber LM, van Luxemburg-Heijs SAP, Veenhof WF, Willemze R, Falkenburg JHF. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood. 1995;86(7):2821-2828.
24. Dodi IA, van Rhee F, Forde HC, et al. CD4(+) bias in T cells cloned from a CML patient with active graft versus leukemia effect. Cytotherapy. 2002;4(4):353-363.
25. Michalek J, Collins RH, Durrani HP, et al. Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A. 2003;100(3):1180-1184. (Pubitemid 36183976)
26. Kloosterboer FM, van Luxemburg-Heijs SAP, van Soest RA, et al. Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia. 2004;18(4):798-808.
27. Soiffer RJ, Alyea EP, Hochberg E, et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002;8(11):625-632. (Pubitemid 35446754)
28. Meyer RG, Britten CM, Wehler D, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood. 2007;109(1):374-382. (Pubitemid 46053080)
29. Rutten CE, van Luxemburg-Heijs SAP, Griffioen M, et al. HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia. 2008;22(7):1387-1394. (Pubitemid 352006083)
30. Kawase T, Nannya Y, Torikai H, et al. Identification of human minor histocompatibility antigens based on genetic association with highly parallel genotyping of pooled DNA. Blood. 2008;111(6):3286-3294.
31. Kamei M, Nannya Y, Torikai H, et al. HapMap scanning of novel human minor histocompatibility antigens. Blood. 2009;113(21):5041-5048.
32. van de Corput L, Chaux P, van der Meijden ED, et al. A novel approach to identify antigens recognized by CD4 T cells using complementopsonized bacteria expressing a cDNA library. Leukemia. 2005;19(2):279-285. (Pubitemid 40220594)
33. Griffioen M, van der Meijden ED, Slager EH, et al. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Proc Natl Acad Sci U S A. 2008;105(10):3837- 3842. (Pubitemid 351723486)
34. Spaapen RM, Lokhorst HM, van den Oudenalder K, et al. Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. J Exp Med. 2008;205(12):2863-2872.
35. Jedema I, Meij P, Steeneveld E, et al. Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay. Clin Cancer Res. 2007;13(2 pt 1):636-643. (Pubitemid 46225371)
36. Davis CA, Benzer S. Generation of cDNA expression libraries enriched for in-frame sequences. Proc Natl Acad Sci U S A. 1997;94(6):2128-2132. (Pubitemid 27136839)
37. Griffioen M, van Egmond HM, Barnby-Porritt H, et al. Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica. 2008;93(10):1535-1543.
38. National Center for Biotechnology Information. Single Nucleotide Polymorphism. http://www.ncbi.nlm.nih.gov/projects/SNP/. Accessed August 2009.
39. National Center for Biotechnology Information. GenBank. http://www.ncbi.nlm.nih.gov/Genbank. Accessed August 2009.
40. Kobayashi H, Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol. 2008;20(2):221-227.
41. Vyas JM, van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol. 2008;8(8):607-618.
42. Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood. 2002;99(8):3027-3032. (Pubitemid 34525395)
43. Michálek J, Collins RH, Hill BJ, Brenchley JM, Douek DC. Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation. Lancet. 2003;361(9364):1183-1185. (Pubitemid 36398389)
44. Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004;199(8):1133-1142. (Pubitemid 38619909)
45. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973-2978.
46. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991;324(10):667-674.
47. Chauhan D, Hideshima T, Pandey P, et al. RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 1999;18(48):6733- 6740.
48. Sarkar S, Svoboda M, de Beaumont R, Freedman AS. The role of Aktand RAFTK in beta1 integrin mediated survival of precursor Bacute lymphoblastic leukemia cells. Leuk Lymphoma. 2002;43(8):1663-1671. (Pubitemid 34823488)
49. Sun CK, Ng KT, Sun BS, et al. The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br J Cancer. 2007;97(1):50-57.
50. Behmoaram E, Bijian K, Jie S, et al. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol. 2008;173(5):1540-1550.
51. Roelle S, Grosse R, Buech T, Chubanov V, Gudermann T. Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells. Oncogene. 2008;27(12):1737-1748.
52. Wu CJ, Yang XF, McLaughlin S, et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000;106(5):705-714. (Pubitemid 30691342)